Israeli-based digital health technology company GrayMatters Health, which develops self-neuromodulation therapies for mental disorders, received FDA 510(k) clearance for its PTSD-focused neuromodulation therapy dubbed Prism.
The company uses a proprietary model to create a unique patient amygdala-derived biomarker, using synchronized data from several sessions of electroencephalograms (EEGs)...
The Queensland Brain Institute under the University of Queensland has developed a remote care platform for monitoring and treating patients with neurological disorders.
WHAT IT DOES
Created in partnership with Neurosciences Queensland and Abbott Neuromodulation, the digital platform allows clinicians to remotely monitor patients and adjust their devices to treat and alleviate their symptoms in...
Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation therapy slowed declines in memory and cognition among mild-to-moderate Alzheimer's disease patients.
The OVERTURE study, a multi-center, randomized controlled trial, enrolled 76 such patients aged 50...
Abbott announced today that it has updated NeuroSphere, its app-driven neuromodulation therapy platform, with remote programming capabilities that will allow patients to speak with and receive adjustments from their provider via a cellular or WiFi connection.
The NeuroSphere Virtual Clinic was recently approved by the FDA and is now available within the Abbott patient controller app for use with...
Abbott has received FDA approval for a neuromodulation system-controller app that runs on iOS devices, the company announced Thursday.
Compatible with Abbott's broader NeuroSphere Digital Care platform, the Patient Controller app replaces the separate device patients use to adjust the company's neuromodulation products. These include the Infinity DBS System for Parkinson's disease or essential...
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round.
Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV.
WHAT THEY DO
Stanford University...
Samsung and Medtronic are once again teaming up, this time to build mobile tools for patients using neuromodulation therapy, a treatment used in a number of chronic conditions including chronic pain, movement disorders, and incontinence.
The two companies partnered in June on diabetes around the same time Medtronic received FDA clearance for its MiniMed Connect device that connects Medtronic CGMs...
